Promethazine VC with Codeine Oral Solution

6 ADVERSE REACTIONS The following serious adverse reactions are described, or described in greater detail, in other sections: Addiction, abuse, and misuse [see Warnings and Precautions ( 5.1 ) and Drug Abuse and Dependence ( 9.3 ) ] Life-threatening respiratory depression [see Warnings and Precautions ( 5.2 , 5.3 , 5.4 , 5.5 , 5.6 ) and Overdosage ( 10 ) ] Ultra-rapid metabolism of codeine and other risk factors for life-threatening respiratory depression in children [see Warnings and Precautions ( 5.3 ) ] Accidental overdose and death due to medication errors [see Warnings and Precautions ( 5.7 ) ] Decreased mental alertness with impaired mental and/or physical abilities [see Warnings and Precautions ( 5.8 ) ] Interactions with benzodiazepines and other CNS depressants [see Warnings and Precautions ( 5.10 ) ] Paralytic ileus, gastrointestinal adverse reactions [see Warnings and Precautions ( 5.11 ) ] Increased intracranial pressure [see Warnings and Precautions ( 5.12 ) ] Obscured clinical course in patients with head injuries [see Warnings and Precautions ( 5.12 ) ] Cardiovascular effects [see Warnings and Precautions ( 5.13 )] Neuroleptic Malignant Syndrome [see Warnings and Precautions ( 5.14 ) ] Paradoxical reactions, including dystonias [see Warnings and Precautions ( 5.15 ) ] Seizures [see Warnings and Precautions ( 5.16 ) ] Interactions with MAOI [see Warnings and Precautions ( 5.17 ) ] Bone-marrow suppression [see Warnings and Precautions ( 5.18 ) ] Severe hypotension [see Warnings and Precautions ( 5.19 ) ] Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions ( 5.20 ) ] Adrenal insufficiency [see Warnings and Precautions ( 5.21 ) ] The following adverse reactions have been identified during clinical studies, in the literature, or during post-approval use of codeine, promethazine, and/or phenylephrine. Because these reactions may be reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most common adverse reactions to Promethazine VC with Codeine Oral Solution include: Sedation (somnolence, mental clouding, lethargy), impaired mental and physical performance, lightheadedness, dizziness, headache, dry mouth, nausea, vomiting, constipation, shortness of breath, sweating, tachycardia, arrhythmias including premature ventricular contractions, CNS stimulation including anxiety, restlessness, nervousness, tremor, and irritability. Other reactions include: Anaphylaxis : Anaphylaxis has been reported with codeine, one of the ingredients in Promethazine VC with Codeine Oral Solution. Body as a whole : Coma, death, fatigue, falling injuries, hyperactivity, hyperthermia, lethargy, weakness. Cardiovascular : Peripheral edema, atrial fibrillation, myocardial infarction, increased blood pressure, decreased blood pressure, tachycardia, chest pain, palpitation, syncope, orthostatic hypotension, prolonged QT interval, hot flush. Central Nervous System : Ataxia, confusion, diplopia, facial dyskinesia, insomnia, migraine, increased intracranial pressure, seizure, tinnitus, tremor, vertigo. Dermatologic : Flushing, hyperhidrosis, photosensitivity, pruritus, rash, urticaria. Endocrine/Metabolic : Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs. Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Cases of androgen deficiency have occurred with chronic use of opioids [see Clinical Pharmacology ( 12.2 ) ]. Gastrointestinal : Abdominal pain, bowel obstruction, decreased appetite, diarrhea, difficulty swallowing, dry mouth, GERD, indigestion, dysguesia, ischemic colitis, jaundice, pancreatitis, paralytic ileus, biliary tract spasm (spasm of the sphincter of Oddi). Genitourinary : Urinary tract infection, ureteral spasm, spasm of vesicle sphincters, urinary retention. Hematologic : Bone-marrow suppression, agranulocytosis, aplastic anemia, and thrombocytopenia have been reported. Laboratory : Increases in serum amylase. Musculoskeletal : Arthralgia, backache, muscle spasm. Ophthalmic : Blurred vision, miosis (constricted pupils), mydriasis (dilated pupils), visual disturbances. Paradoxical Reactions : Dystonias, torticollis, tongue protrusion, hyperexcitability, and abnormal movements have been reported following a single administration of promethazine. Psychiatric : Agitation, anxiety, confusion, fear, dysphoria, depression, hallucinations. Reproductive : Hypogonadism, infertility. Respiratory : Apnea, bronchitis, cough, dry nose, dry throat, dyspnea, nasal congestion, nasopharyngitis, respiratory depression, sinusitis, thickening of bronchial secretions, tightness of chest and wheezing, upper respiratory tract infection. Other : Drug abuse, drug dependence, Neuroleptic Malignant Syndrome, opioid withdrawal syndrome. Common adverse reactions include: Sedation (somnolence, mental clouding, lethargy), impaired mental and physical performance, lightheadedness, dizziness, headache, dry mouth, nausea, vomiting, constipation, shortness of breath, sweating, tachycardia, arrhythmias including premature ventricular contractions, CNS stimulation including anxiety, restlessness, nervousness, tremor, and irritability. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Pharmaceutical Associates, Inc. at 1-800-845-8210 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

4 CONTRAINDICATIONS Promethazine VC with Codeine Oral Solution is contraindicated for: • All children younger than 12 years of age [ see Warnings and Precautions ( 5.2 , 5.3, 5.5 ), Use in Specific Populations ( 8.4 ) ]. • Postoperative pain management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [ see Warnings and Precautions ( 5.2 , 5.3) ]. Promethazine VC with Codeine Oral Solution is also contraindicated in patients with: • Significant respiratory depression [ see Warnings and Precautions ( 5.2 ) ]. • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [ see Warnings and Precautions ( 5.6) ]. • Known or suspected gastrointestinal obstruction, including paralytic ileus [ see Warnings and Precautions ( 5.11 ) ]. • Narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease, or peripheral vascular insufficiency (ischemia may result with risk of gangrene or thrombosis of compromised vascular beds) [ see Warnings and Precautions ( 5.13 )]. • A history of an idiosyncratic reaction to promethazine or to other phenothiazines [ see Warnings and Precautions ( 5.15 ) ]. • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within 14 days [ see Warnings and Precautions ( 5.17 ) and Drug Interactions ( 7.6 ) ]. • Hypersensitivity to codeine, promethazine, phenylephrine, or any of the inactive ingredients in Promethazine VC with Codeine Oral Solution [ see Adverse Reactions ( 6 ) ]. Persons known to be hypersensitive to certain other opioids may exhibit cross-reactivity to codeine. Children younger than 12 years of age. ( 4 ) Significant respiratory depression. ( 4 ) Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment. ( 4 ) Known or suspected gastrointestinal obstruction, including paralytic ileus. ( 4 ) Patients with narrow angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease, or peripheral vascular insufficiency. ( 4 ) Concurrent use of monoamine oxidase inhibitor (MAOI) therapy or within the last 14 days. ( 4 ) History of an idiosyncratic reaction to promethazine or to other phenothiazines. ( 4 ) Hypersensitivity to codeine or other opiates, promethazine, phenylephrine, or any of the inactive ingredients in Promethazine VC with Codeine Oral Solution. ( 4 )

11 DESCRIPTION Promethazine VC with Codeine Oral Solution (promethazine hydrochloride, phenylephrine hydrochloride, and codeine phosphate) oral solution contains codeine an opioid agonist; promethazine, a phenothiazine; and phenylephrine, an alpha-1 adrenergic receptor agonist. Each 5 mL of Promethazine VC with Codeine Oral Solution contains 10 mg of codeine phosphate, 6.25 mg of promethazine hydrochloride, and 5 mg of phenylephrine hydrochloride for oral administration. Promethazine VC with Codeine Oral Solution has a pH between 4.4 and 5.2 and contains alcohol 7%. Promethazine VC with Codeine Oral Solution also contains the following inactive ingredients: Ascorbic acid, citric acid, D&C Red #33, FD&C Yellow #6, menthol, methylparaben, propylene glycol, propylparaben, purified water, saccharin sodium, sodium benzoate, sodium citrate, strawberry flavor and sucrose. Codeine Phosphate The chemical name for codeine phosphate is 7,8-Didehydro-4, 5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol phosphate (1:1) (salt) hemihydrate. Codeine is one of the naturally occurring phenanthrene alkaloids of opium derived from the opium poppy, it is classified pharmacologically as a narcotic analgesic. The phosphate salt of codeine occurs as white, needle-shaped crystals or white crystalline powder. Codeine phosphate is freely soluble in water and slightly soluble in alcohol. The molecular weight is 406.37. Its molecular formula is C 18 H 21 NO 3 •H 3 PO 4 • ½ H 2 O, and it has the following chemical structure. Promethazine Hydrochloride The chemical name for promethazine hydrochloride, a phenothiazine derivative, is (±)-10-[2-(Dimethylamino)propyl] phenothiazine monohydrochloride. Promethazine hydrochloride occurs as a white to faint yellow, practically odorless, crystalline powder which slowly oxidizes and turns blue on prolonged exposure to air. It is soluble in water and freely soluble in alcohol. The molecular weight is 320.88. Its molecular formula is C 17 H 20 N 2 S•HCl, and it has the following chemical structure. Phenylephrine Hydrochloride The chemical name for phenylephrine hydrochloride, a sympathomimetic amine salt, is (-)- m -hydroxy-α-[(methyl-amino)methyl] benzyl alcohol hydrochloride. It occurs as white or nearly white crystals, having a bitter taste. It is freely soluble in water and alcohol. Phenylephrine hydrochloride is subject to oxidation and must be protected from light and air. The molecular weight is 203.67. Its molecular formula is C 9 H 13 NO 2 • HCl, and it has the following chemical structure. Codeine chemical structure Promethazine hydrochloride chemical structure Phenylephrine hydrochloride chemical structure

2 DOSAGE AND ADMINISTRATION Adults 18 years of age and older : 5 mL every 4 to 6 hours as needed, not to exceed 6 doses (30 mL) in 24 hours. ( 2.2 ) Measure Promethazine VC with Codeine Oral Solution with an accurate milliliter measuring device. ( 2.1 , 5.7 ) Do not increase the dose or dosing frequency. ( 2.1 ) Prescribe for the shortest duration consistent with treatment goals. ( 2.3 ) Reevaluate patients with unresponsive cough in 5 days or sooner for possible underlying pathology. ( 2.3 ) Reevaluate patient prior to refilling. ( 2.3 ) 2.1 Important Dosage and Administration Instructions Administer Promethazine VC with Codeine Oral Solution by the oral route only. Always use an accurate milliliter measuring device when administering Promethazine VC with Codeine Oral Solution to ensure that the dose is measured and administered accurately. A household teaspoon is not an accurate measuring device and could lead to overdosage [ see Warnings and Precautions ( 5.7 ) ]. For prescriptions where a measuring device is not provided, a pharmacist can provide an appropriate measuring device and can provide instructions for measuring the correct dose. Do not overfill. Rinse the measuring device with water after each use. Advise patients not to increase the dose or dosing frequency of Promethazine VC with Codeine Oral Solution because serious adverse events such as respiratory depression may occur with overdosage [ see Warnings and Precautions ( 5.1 ) and Overdosage ( 10 ) ]. The dosage of Promethazine VC with Codeine Oral Solution should not be increased if cough fails to respond; an unresponsive cough should be reevaluated for possible underlying pathology [ see Dosage and Administration ( 2.3 ) and Warnings and Precautions ( 5.6) ]. 2.2 Recommended Dosage Adults 18 years of age and older: 5 mL every 4 to 6 hours as needed, not to exceed 6 doses (30 mL) in 24 hours. 2.3 Monitoring, Maintenance, and Discontinuation of Therapy Prescribe Promethazine VC with Codeine Oral Solution for the shortest duration that is consistent with individual patient treatment goals [ see Warnings and Precautions ( 5.1 ) ]. Monitor patients closely for respiratory depression, especially within the first 24 - 72 hours of initiating therapy [ see Warnings and Precautions ( 5.2 )] . Reevaluate patients with unresponsive cough in 5 days or sooner for possible underlying pathology, such as foreign body or lower respiratory tract disease [see Warnings and Precautions (5.6)]. If a patient requires a refill, reevaluate the cause of the cough and assess the need for continued treatment with Promethazine VC with Codeine Oral Solution, the relative incidence of adverse reactions, and the development of addiction, abuse, or misuse [ see Warnings and Precautions ( 5.1 ) ]. Do not abruptly discontinue Promethazine VC with Codeine Oral Solution in a physically-dependent patient [see Drug Abuse and Dependence ( 9.3 ) ]. When a patient who has been taking Promethazine VC with Codeine Oral Solution regularly and may be physically dependent no longer requires therapy with Promethazine VC with Codeine Oral Solution, taper the dose gradually, by 25% to 50% every 2 to 4 days, while monitoring carefully for signs and symptoms of withdrawal. If the patient develops these signs or symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both.

1 INDICATIONS AND USAGE Promethazine VC with Codeine Oral Solution is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold in patients 18 years of age and older. Important Limitations of Use • Not indicated for pediatric patients under 18 years of age [see Use in Specific Populations (8.4)]. • Contraindicated in pediatric patients under 12 years of age [see Contraindications (4) and Use in Specific Populations (8.4)]. • Contraindicated in pediatric patients 12 to 18 years of age after tonsillectomy or adenoidectomy [see Contraindications (4) and Use in Specific Populations (8.4)]. • Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1)], reserve Promethazine VC with Codeine Oral Solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks,and in whom an adequate assessment of the etiology of the cough has been made. Promethazine VC with Codeine Oral Solution is a combination of codeine, an opioid agonist; promethazine, a phenothiazine; and phenylephrine, an alpha-1 adrenergic receptor agonist, indicated for the temporary relief of cough and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold in patients 18 years of age and older. ( 1 ) Important Limitations of Use ( 1 ) Not indicated for pediatric patients under 18 years of age. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve Promethazine VC with Codeine Oral Solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made.

9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance Promethazine VC with Codeine Oral Solution contains codeine, a Schedule V controlled substance. 9.2 Abuse Codeine Promethazine VC with Codeine Oral Solution contains codeine, a substance with a high potential for abuse similar to other opioids including morphine and codeine. Promethazine VC with Codeine Oral Solution can be abused and is subject to misuse, addiction, and criminal diversion [see Warnings and Precautions ( 5.1 ) ]. All patients treated with opioids require careful monitoring for signs of abuse and addiction, since use of opioid analgesic and antitussive products carries the risk of addiction even under appropriate medical use. Prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and includes: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal. “Drug-seeking” behavior is very common in persons with substance use disorders. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing, or referral, repeated “loss” of prescriptions, tampering with prescriptions, and reluctance to provide prior medical records or contact information for other treating health care provider(s). “Doctor shopping” (visiting multiple prescribers to obtain additional prescriptions) is common among drug abusers and people suffering from untreated addiction. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control. Abuse and addiction are separate and distinct from physical dependence and tolerance. Health care providers should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction. Promethazine VC with Codeine Oral Solution, like other opioids, can be diverted for non-medical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised. Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs. Risks Specific to Abuse of Promethazine VC with Codeine Oral Solution Promethazine VC with Codeine Oral Solution is for oral use only. Abuse of Promethazine VC with Codeine Oral Solution poses a risk of overdose and death. The risk is increased with concurrent use of Promethazine VC with Codeine Oral Solution with alcohol and other central nervous system depressants [see Warnings and Precautions ( 5.10 )]. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV. 9.3 Dependence Psychological dependence, physical dependence, and tolerance may develop upon repeated administration of opioids; therefore, Promethazine VC with Codeine Oral Solution should be prescribed and administered for the shortest duration that is consistent with individual patient treatment goals and patients should be reevaluated prior to refills [see Dosage and Administration ( 2.3 ) and Warnings and Precautions ( 5.1 ) ]. Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral opioid use, although some mild degree of physical dependence may develop after a few days of opioid therapy. If Promethazine VC with Codeine Oral Solution is abruptly discontinued in a physically-dependent patient, a withdrawal syndrome may occur. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity (eg, naloxone, nalmefene), mixed agonist/antagonist analgesics (eg, pentazocine, butorphanol, nalbuphine), or partial agonists (eg, buprenorphine). Some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal signs [see Use in Specific Populations ( 8.1 ) ].

10 OVERDOSAGE Clinical Presentation Codeine Acute overdose with codeine is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, partial or complete airway obstruction, atypical snoring, hypotension, circulatory collapse, cardiac arrest, and death. Codeine may cause miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (eg, pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations [see Clinical Pharmacology ( 12.2 ) ]. Promethazine Signs and symptoms of overdosage with promethazine range from mild depression of the central nervous system and cardiovascular system to profound hypotension, respiratory depression, unconsciousness and sudden death. Other reported reactions include hyperreflexia, hypertonia, ataxia, athetosis and extensor-plantar reflexes (Babinski reflex). Stimulation may be evident, especially in children and geriatric patients. Convulsions may rarely occur. A paradoxical reaction has been reported in children receiving single doses of 75 mg to 125 mg orally, characterized by hyperexcitability and nightmares. Atropine-like signs and symptoms (dry mouth, fixed dilated pupils, flushing, tachycardia, hallucinations, gastrointestinal symptoms, convulsions, urinary retention, cardiac arrhythmias and coma) may be observed. Impaired secretion from sweat glands following toxic doses of drugs with anticholinergic side effects may predispose to hyperthermia. Phenylephrine Signs and symptoms of overdosage with phenylephrine include headache, vomiting, hypertension, reflex bradycardia, cardiac arrhythmias including ventricular premature beats and ventricular tachycardia, convulsions, and cerebral hemorrhage. Overdosage may also be associated with a sensation of fullness in the head and tingling of the extremities. Headache may be a symptom of hypertension. Bradycardia may be seen early in phenylephrine overdosage through stimulation of baroreceptors. Treatment of Overdose Treatment of overdosage is driven by the overall clinical presentation, and consists of discontinuation of Promethazine VC with Codeine Oral Solution together with institution of appropriate therapy. Give primary attention to the reestablishment of adequate respiratory exchange through provision of a patent and protected airway and the institution of assisted or controlled ventilation. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support techniques. Gastric emptying may be useful in removing unabsorbed drug. The opioid antagonists, naloxone and nalmefene, are specific antidotes for respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to codeine overdose, administer an opioid antagonist. An antagonist should not be administered in the absence of clinically significant respiratory depression. Because the duration of opioid reversal is expected to be less than the duration of action of codeine in Promethazine VC with Codeine Oral Solution, carefully monitor the patient until spontaneous respiration is reliably reestablished. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product’s prescribing information. The respiratory depressant effects of promethazine are not reversed by opioid antagonists, such as naloxone. Because of the potential for promethazine to reverse epinephrine’s vasopressor effect, epinephrine should NOT be used to treat hypotension associated with promethazine overdose. Hemodialysis is not routinely used to enhance the elimination of codeine or promethazine from the body. Adrenergic receptor blocking agents (beta-blockers), such as propranolol, may be used for the treatment of cardiac toxicity due to phenylephrine.

7 DRUG INTERACTIONS No specific drug interaction studies have been conducted with Promethazine VC with Codeine Oral Solution. Serotonergic Drugs : Concomitant use may result in serotonin syndrome. Discontinue if serotonin syndrome is suspected. ( 7.5 ) Muscle relaxants : Avoid concomitant use. ( 7.7 ) Diuretics : Codeine may reduce the efficacy of diuretics. Monitor for reduced effect. ( 7.8 ) Anticholinergic drugs : Concurrent use may cause paralytic ileus. ( 5.11 , 7.9 ) Antihypertensive drugs : Concomitant use may interfere with antihypertensive effects. ( 7.10 ) Ergot alkaloids, atropine sulfate, steroids, angiotensin, aldosterone, norepinephrine transporter inhibitors, and tricyclic antidepressants : Concomitant use may enhance the pressor response and increase the risk of hypertension. ( 7.11 ) Sympathomimetic Agents : Concomitant use may result in tachycardia, arrhythmias, serious hypertensive response and possible stroke. ( 7.12 ) 7.1 Inhibitors of CYP3A4 The concomitant use of Promethazine VC with Codeine Oral Solution with CYP3A4 inhibitors, such as macrolide antibiotics (eg, erythromycin), azole-antifungal agents (eg, ketoconazole), or protease inhibitors (eg, ritonavir), may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of Promethazine VC with Codeine Oral Solution is achieved [see Warnings and Precautions ( 5.9 ) ]. After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels [see Clinical Pharmacology ( 12.3 ) ], resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to codeine. Avoid the use of Promethazine VC with Codeine Oral Solution while taking a CYP3A4 inhibitor. If concomitant use is necessary, monitor patients for respiratory depression and sedation at frequent intervals. 7.2 CYP3A4 Inducers The concomitant use of Promethazine VC with Codeine Oral Solution and CYP3A4 inducers, such as rifampin, carbamazepine, or phenytoin, can result in lower codeine levels, greater norcodeine levels, and less metabolism via 2D6 with resultant lower morphine levels [see Clinical Pharmacology ( 12.3 ) ], resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence [see Warnings and Precautions ( 5.9 ) ]. After stopping a CYP3A4 inducer, as the effects of the inducer decline, codeine plasma concentrations may increase with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels [see Clinical Pharmacology ( 12.3 ) ], which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression. Avoid the use of Promethazine VC with Codeine Oral Solution in patients who are taking CYP3A4 inducers. If concomitant use of a CYP3A4 inducer is necessary, follow the patient for reduced efficacy. 7.3 Inhibitors of CYP2D6 Codeine is metabolized by CYP2D6 to form morphine. The concomitant use of Promethazine VC with Codeine Oral Solution and CYP2D6 inhibitors, such as paroxetine, fluoxetine, bupropion, or quinidine, can increase the plasma concentration of codeine, but can decrease the plasma concentration of active metabolite morphine, which could result in reduced efficacy [see Clinical Pharmacology ( 12.3 ) ]. After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the codeine plasma concentration will decrease but the active metabolite morphine plasma concentration will increase, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression [see Clinical Pharmacology ( 12.3 ) ]. Avoid the use of Promethazine VC with Codeine Oral Solution in patients who are taking inhibitors of CYP2D6. 7.4 Benzodiazepines and Other CNS Depressants Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, and other opioids, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. Avoid the use of Promethazine VC with Codeine Oral Solution in patients who are taking benzodiazepines or other CNS depressants [see Warnings and Precautions ( 5.10 ) ]. 7.5 Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation. Discontinue Promethazine VC with Codeine Oral Solution if serotonin syndrome is suspected. 7.6 Monoamine Oxidase Inhibitors (MAOIs) Promethazine VC with Codeine Oral Solution is contraindicated in patients who are taking MAOIs (ie, certain drugs used for depression, psychiatric or emotional conditions, or Parkinson’s disease) or have taken MAOIs within 14 days [see Contraindications ( 4 ) ]. MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (eg, respiratory depression, coma) [see Warnings and Precautions ( 5.17 ) ]. The cardiac pressor response may be potentiated and acute hypertensive crisis may occur when phenylephrine containing preparations are used with prior administration of MAOIs [see Warnings and Precautions ( 5.17 ) ]. Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly. 7.7 Muscle Relaxants Codeine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Avoid the use of Promethazine VC with Codeine Oral Solution in patients taking muscle relaxants. If concomitant use is necessary, monitor patients for signs of respiratory depression that may be greater than otherwise expected. 7.8 Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed. 7.9 Anticholinergic Drugs The concomitant use of anticholinergic drugs with Promethazine VC with Codeine Oral Solution may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus [see Warnings and Precautions ( 5.11 ) ]. Monitor patients for signs of urinary retention or reduced gastric motility when Promethazine VC with Codeine Oral Solution is used concomitantly with anticholinergic drugs. Additive adverse effects resulting from cholinergic blockade (eg, xerostomia, blurred vision, or constipation) may occur when anticholinergic drugs are administered with promethazine. 7.10 Antihypertensive Drugs Due to the antagonistic pharmacologic effects of phenylephrine, one of the active ingredients in Promethazine VC with Codeine Oral Solution, the concomitant use of Promethazine VC with Codeine Oral Solution with antihypertensive drugs, including alpha-adrenergic antagonists (eg, phentolamine); mixed alpha- and beta-adrenoreceptor antagonists; calcium channel blockers (eg, nifedipine); ACE inhibitors; and centrally acting sympatholytic agents (eg, guanfacine, reserpine) may reduce their antihypertensive effects. Use Promethazine VC with Codeine Oral Solution with caution in patients who are taking antihypertensive drugs. 7.11 Interactions that Augment the Pressor Effect of Phenylephrine The concomitant use of Promethazine VC with Codeine Oral Solution with ergot alkaloids (eg, methylergonovine maleate); atropine sulfate; steroids (eg, hydrocortisone); angiotensin; aldosterone; norepinephrine transporter inhibitors (eg, atomoxetine); and tricyclic antidepressants may enhance the pressor response and increase the risk of hypertension. Use Promethazine VC with Codeine Oral Solution with caution in patients who are taking such drugs. 7.12 Sympathomimetic Agents Due to synergistic adrenergic effects of phenylephrine, one of the active ingredients in Promethazine VC with Codeine Oral Solution, the concomitant use of Promethazine VC with Codeine Oral Solution with sympathomimetic amines such as epinephrine, amphetamine, phenylpropanolamine, and bronchodilator beta2-adrenoreceptor agonists may result in tachycardia, arrhythmias, serious hypertensive response and possible stroke. Use Promethazine VC with Codeine Oral Solution with caution in patients who are taking sympathomimetic agents.

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Codeine Codeine is an opioid agonist relatively selective for the mu-opioid receptor, but with a much weaker affinity than morphine. The analgesic and antitussive properties of codeine have been speculated to come from its conversion to morphine. The precise mechanism of action of codeine and other opiates is not known; however, codeine is believed to act centrally on the cough center. In excessive doses, codeine will depress respiration. Promethazine Promethazine is a phenothiazine derivative, which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. Promethazine possesses antihistamine (H 1 receptor antagonist), antiemetic, sedative, and anticholinergic effects. It prevents released histamine from dilating capillaries and causing edema of the respiratory mucosa. Phenylephrine Phenylephrine is a sympathomimetic amine that exerts a decongestant action on the nasal mucosa via alpha adrenergic receptor activity. It has the potential for excitatory side effects. 12.2 Pharmacodynamics Codeine Effects on the Central Nervous System Codeine produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and to electrical stimulation. Codeine causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (eg, pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations. Effects on the Gastrointestinal Tract and Other Smooth Muscle Codeine causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase. Effects on the Cardiovascular System Codeine produces peripheral vasodilation which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes and sweating and/or orthostatic hypotension. Effects on the Endocrine System Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans [ see Adverse Reactions ( 6 ) ]. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon. Chronic use of opioids may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date [ see Adverse Reactions ( 6 ) ]. Effects on the Immune System Opioids have been shown to have a variety of effects on components of the immune system in in vitro and animal models. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive. Concentration–Adverse Reaction Relationships There is a relationship between increasing codeine plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions. Promethazine Promethazine competitively antagonizes H 1 receptors located in most of the smooth muscle including the gastrointestinal tract, uterus, large blood vessels and bronchial muscle. Actions of histamine on H 1 receptors increases capillary permeability and edema formation, flare and pruritus. Phenylephrine Interaction of phenylephrine with alpha-1 adrenergic receptors on vascular smooth muscle cells causes activation of the cells and results in vasoconstriction. Following oral administration or topical application of phenylephrine to the mucosa, constriction of blood vessels in the nasal mucosa relieves nasal congestion associated with allergy or head colds. Following oral administration, nasal decongestion may occur within 15 or 20 minutes and may persist for up to 4 hours. Phenylephrine increases resistance and, to a lesser extent, decreases capacitance of blood vessels. Total peripheral resistance is increased, resulting in increased systolic and diastolic blood pressure. Pulmonary arterial pressure is usually increased, and renal blood flow is usually decreased. Local vasoconstriction and hemostasis occur following topical application or infiltration of phenylephrine into tissues. The main effect of phenylephrine on the heart is bradycardia; it produces a positive inotropic effect on the myocardium in doses greater than those usually used therapeutically. Rarely, the drug may increase the irritability of the heart, causing arrhythmias. Cardiac output is decreased slightly. Phenylephrine increases the work of the heart by increasing peripheral arterial resistance. Phenylephrine has a mild central stimulant effect [ see Adverse Reactions ( 6 ) ]. 12.3 Pharmacokinetics Absorption Codeine is absorbed from the gastrointestinal tract with maximum plasma concentration occurring 60 minutes post administration. The presence of a high-fat, high-calorie meal did not significantly impact the PK of codeine. Promethazine is well absorbed from the gastrointestinal tract. Clinical effects are apparent within 20 minutes after oral administration and generally last four to six hours, although they may persist as long as 12 hours. Phenylephrine is irregularly absorbed from and readily metabolized in the gastrointestinal tract. Distribution Codeine has been reported to have an apparent volume of distribution of approximately 3 to 6 L/kg, indicating extensive distribution of the drug into tissues. Codeine has low plasma protein binding with about 7 to 25% of codeine bound to plasma proteins. Codeine passes the blood brain barrier and the placental barrier. Small amounts of codeine and its metabolite, morphine, are transferred to human breast milk. Promethazine is widely distributed in body tissues. Promethazine has high protein binding with about 80 to 93% of promethazine bound to plasma proteins. Promethazine passes the blood brain barrier and the placental barrier. Phenylephrine is highly distributed in peripheral tissues and organs with a steady-state volume of distribution of approximately 340 L following intravenous administration. Penetration into the blood brain barrier is minimal. Elimination Metabolism Codeine is metabolized by conjugation with glucuronic acid to codeine-6-glucuronide (about 70 to 80%), by O-demethylation to morphine (about 5 to 10%), and by N-demethylation to norcodeine (about 10%). UDP-glucuronosyltransferase (UGT) 2B7 and 2B4 are the major enzymes mediating glucuronidation of codeine to C6G. Cytochrome P450 2D6 is the major enzyme responsible for conversion of codeine to morphine and P450 3A4 is the major enzyme mediating conversion of codeine to norcodeine. Morphine and norcodeine are further metabolized by conjugation with glucuronic acid. The glucuronide metabolites of morphine are morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). Morphine and its M6 glucuronide conjugate are pharmacologically active. Whether C6G has pharmacological activity is unknown. Norcodeine and M3 glucuronide conjugate of morphine are generally not considered to be pharmacologically active. Promethazine is metabolized by the liver to a variety of inactive metabolites such as sulfoxides of promethazine, N-demethylpromethazine and other glucuronides. Phenylephrine is metabolized primarily by monoamine oxidase and sulfotransferase in the intestinal wall and liver. There are two major metabolites, m -hydroxymandelic acid and sulfate conjugates, that are considered not pharmacologically active. Excretion Approximately 90% of the total dose of codeine is excreted through the kidneys, of which approximately 10% is unchanged codeine. Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours. Promethazine has an elimination half-life of 10-14 hours, with excretion of metabolites appearing in the urine and feces. The sulfoxides of promethazine and N-demethylpromethazine are the predominant metabolites appearing in the urine. Phenylephrine and metabolites are excreted mainly in the urine within 48 hours. The mean elimination half-life of phenylephrine is around 2.5 hours.

12.1 Mechanism of Action Codeine Codeine is an opioid agonist relatively selective for the mu-opioid receptor, but with a much weaker affinity than morphine. The analgesic and antitussive properties of codeine have been speculated to come from its conversion to morphine. The precise mechanism of action of codeine and other opiates is not known; however, codeine is believed to act centrally on the cough center. In excessive doses, codeine will depress respiration. Promethazine Promethazine is a phenothiazine derivative, which differs structurally from the antipsychotic phenothiazines by the presence of a branched side chain and no ring substitution. Promethazine possesses antihistamine (H 1 receptor antagonist), antiemetic, sedative, and anticholinergic effects. It prevents released histamine from dilating capillaries and causing edema of the respiratory mucosa. Phenylephrine Phenylephrine is a sympathomimetic amine that exerts a decongestant action on the nasal mucosa via alpha adrenergic receptor activity. It has the potential for excitatory side effects.

12.2 Pharmacodynamics Codeine Effects on the Central Nervous System Codeine produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and to electrical stimulation. Codeine causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (eg, pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations. Effects on the Gastrointestinal Tract and Other Smooth Muscle Codeine causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase. Effects on the Cardiovascular System Codeine produces peripheral vasodilation which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes and sweating and/or orthostatic hypotension. Effects on the Endocrine System Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans [ see Adverse Reactions ( 6 ) ]. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon. Chronic use of opioids may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date [ see Adverse Reactions ( 6 ) ]. Effects on the Immune System Opioids have been shown to have a variety of effects on components of the immune system in in vitro and animal models. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive. Concentration–Adverse Reaction Relationships There is a relationship between increasing codeine plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions. Promethazine Promethazine competitively antagonizes H 1 receptors located in most of the smooth muscle including the gastrointestinal tract, uterus, large blood vessels and bronchial muscle. Actions of histamine on H 1 receptors increases capillary permeability and edema formation, flare and pruritus. Phenylephrine Interaction of phenylephrine with alpha-1 adrenergic receptors on vascular smooth muscle cells causes activation of the cells and results in vasoconstriction. Following oral administration or topical application of phenylephrine to the mucosa, constriction of blood vessels in the nasal mucosa relieves nasal congestion associated with allergy or head colds. Following oral administration, nasal decongestion may occur within 15 or 20 minutes and may persist for up to 4 hours. Phenylephrine increases resistance and, to a lesser extent, decreases capacitance of blood vessels. Total peripheral resistance is increased, resulting in increased systolic and diastolic blood pressure. Pulmonary arterial pressure is usually increased, and renal blood flow is usually decreased. Local vasoconstriction and hemostasis occur following topical application or infiltration of phenylephrine into tissues. The main effect of phenylephrine on the heart is bradycardia; it produces a positive inotropic effect on the myocardium in doses greater than those usually used therapeutically. Rarely, the drug may increase the irritability of the heart, causing arrhythmias. Cardiac output is decreased slightly. Phenylephrine increases the work of the heart by increasing peripheral arterial resistance. Phenylephrine has a mild central stimulant effect [ see Adverse Reactions ( 6 ) ].

12.3 Pharmacokinetics Absorption Codeine is absorbed from the gastrointestinal tract with maximum plasma concentration occurring 60 minutes post administration. The presence of a high-fat, high-calorie meal did not significantly impact the PK of codeine. Promethazine is well absorbed from the gastrointestinal tract. Clinical effects are apparent within 20 minutes after oral administration and generally last four to six hours, although they may persist as long as 12 hours. Phenylephrine is irregularly absorbed from and readily metabolized in the gastrointestinal tract. Distribution Codeine has been reported to have an apparent volume of distribution of approximately 3 to 6 L/kg, indicating extensive distribution of the drug into tissues. Codeine has low plasma protein binding with about 7 to 25% of codeine bound to plasma proteins. Codeine passes the blood brain barrier and the placental barrier. Small amounts of codeine and its metabolite, morphine, are transferred to human breast milk. Promethazine is widely distributed in body tissues. Promethazine has high protein binding with about 80 to 93% of promethazine bound to plasma proteins. Promethazine passes the blood brain barrier and the placental barrier. Phenylephrine is highly distributed in peripheral tissues and organs with a steady-state volume of distribution of approximately 340 L following intravenous administration. Penetration into the blood brain barrier is minimal. Elimination Metabolism Codeine is metabolized by conjugation with glucuronic acid to codeine-6-glucuronide (about 70 to 80%), by O-demethylation to morphine (about 5 to 10%), and by N-demethylation to norcodeine (about 10%). UDP-glucuronosyltransferase (UGT) 2B7 and 2B4 are the major enzymes mediating glucuronidation of codeine to C6G. Cytochrome P450 2D6 is the major enzyme responsible for conversion of codeine to morphine and P450 3A4 is the major enzyme mediating conversion of codeine to norcodeine. Morphine and norcodeine are further metabolized by conjugation with glucuronic acid. The glucuronide metabolites of morphine are morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). Morphine and its M6 glucuronide conjugate are pharmacologically active. Whether C6G has pharmacological activity is unknown. Norcodeine and M3 glucuronide conjugate of morphine are generally not considered to be pharmacologically active. Promethazine is metabolized by the liver to a variety of inactive metabolites such as sulfoxides of promethazine, N-demethylpromethazine and other glucuronides. Phenylephrine is metabolized primarily by monoamine oxidase and sulfotransferase in the intestinal wall and liver. There are two major metabolites, m -hydroxymandelic acid and sulfate conjugates, that are considered not pharmacologically active. Excretion Approximately 90% of the total dose of codeine is excreted through the kidneys, of which approximately 10% is unchanged codeine. Plasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours. Promethazine has an elimination half-life of 10-14 hours, with excretion of metabolites appearing in the urine and feces. The sulfoxides of promethazine and N-demethylpromethazine are the predominant metabolites appearing in the urine. Phenylephrine and metabolites are excreted mainly in the urine within 48 hours. The mean elimination half-life of phenylephrine is around 2.5 hours.

20230127

3

3 DOSAGE FORMS AND STRENGTHS Oral solution: Each 5 mL contains codeine phosphate, 10 mg; promethazine hydrochloride 6.25 mg; and phenylephrine hydrochloride, 5 mg, in a flavored syrup base [ see Description ( 11 ) ]. Oral solution: Each 5 mL contains codeine phosphate, 10 mg; promethazine hydrochloride 6.25 mg; phenylephrine hydrochloride 5 mg, in a flavored syrup base. ( 3 )

Promethazine VC with Codeine Oral Solution Promethazine and Phenylephrine Hydrochloride and Codeine Phosphate CODEINE PHOSPHATE CODEINE ANHYDROUS PROMETHAZINE HYDROCHLORIDE PROMETHAZINE PHENYLEPHRINE HYDROCHLORIDE PHENYLEPHRINE ALCOHOL ASCORBIC ACID ANHYDROUS CITRIC ACID D&C RED NO. 33 FD&C YELLOW NO. 6 MENTHOL METHYLPARABEN PROPYLENE GLYCOL PROPYLPARABEN WATER SACCHARIN SODIUM SODIUM BENZOATE SODIUM CITRATE SUCROSE Clear-Reddish

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity, mutagenicity, and fertility studies have not been conducted with Promethazine VC with Codeine Oral Solution; however, published information is available for the individual active ingredients. Codeine Carcinogenicity studies were conducted with codeine. Two-year studies in F344/N rats and B6C3F1 mice were conducted to assess the carcinogenic potential of codeine. No evidence of tumorigenicity was observed in male and female rats at codeine dietary doses up to 70 and 80 mg/kg/day (approximately equivalent to 15 and 18 times, the MRHD on a mg/m 2 basis, respectively). No evidence of tumorigenicity was observed in male and female mice at codeine dietary doses up to 400 mg/kg/day (approximately equivalent to 44 times the MRHD on a mg/m 2 basis). Codeine was not mutagenic in the in vitro bacterial reverse mutation assay or clastogenic in the in vitro Chinese hamster ovary (CHO) cell chromosomal aberration assay. Fertility studies with codeine have not been conducted. Promethazine Carcinogenicity studies were conducted with promethazine hydrochloride. Two-year studies in F344/N rats and B6C3F1 mice were conducted to assess the carcinogenic potential of promethazine hydrochloride. No evidence of tumorigenicity was observed in male and female rats at promethazine hydrochloride oral doses up to 33 mg/kg/day for 5 days/week (approximately equivalent to 10 times the MRHD on a mg/m 2 basis). No evidence of tumorigenicity was observed in male and female mice at promethazine hydrochloride oral doses up to 45 and 15 mg/kg/day for 5 days/week (approximately equivalent to 7 and 2 times the MRHD on a mg/m 2 basis, respectively). Promethazine hydrochloride was not mutagenic in the in vitro bacterial reverse mutation assay or clastogenic in the in vitro Chinese hamster ovary (CHO) cell chromosomal aberration assay. Fertility studies with promethazine have not been conducted. Phenylephrine Carcinogenicity studies were conducted with phenylephrine hydrochloride. Two-year studies in F344/N rats and B6C3F1 mice were conducted to assess the carcinogenic potential of phenylephrine hydrochloride. No evidence of tumorigenicity was observed in male and female rats at phenylephrine hydrochloride dietary doses up to 50 mg/kg/day (approximately equivalent to 20 times the MRHD on a mg/m 2 basis). No evidence of tumorigenicity was observed in male and female mice at phenylephrine hydrochloride dietary doses up to 270 mg/kg/day (approximately equivalent to 55 times the MRHD on a mg/m 2 basis). Phenylephrine hydrochloride tested negative in the in vitro bacterial reverse mutation assay, in vitro Chinese hamster ovary (CHO) cell chromosomal aberrations assay, and in vivo rat micronucleus assay. Phenylephrine hydrochloride was equivocal in the in vitro mouse lymphoma assay without metabolic activation; however, a test with metabolic activation was not performed. Fertility studies with phenylephrine have not been conducted.

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity, mutagenicity, and fertility studies have not been conducted with Promethazine VC with Codeine Oral Solution; however, published information is available for the individual active ingredients. Codeine Carcinogenicity studies were conducted with codeine. Two-year studies in F344/N rats and B6C3F1 mice were conducted to assess the carcinogenic potential of codeine. No evidence of tumorigenicity was observed in male and female rats at codeine dietary doses up to 70 and 80 mg/kg/day (approximately equivalent to 15 and 18 times, the MRHD on a mg/m 2 basis, respectively). No evidence of tumorigenicity was observed in male and female mice at codeine dietary doses up to 400 mg/kg/day (approximately equivalent to 44 times the MRHD on a mg/m 2 basis). Codeine was not mutagenic in the in vitro bacterial reverse mutation assay or clastogenic in the in vitro Chinese hamster ovary (CHO) cell chromosomal aberration assay. Fertility studies with codeine have not been conducted. Promethazine Carcinogenicity studies were conducted with promethazine hydrochloride. Two-year studies in F344/N rats and B6C3F1 mice were conducted to assess the carcinogenic potential of promethazine hydrochloride. No evidence of tumorigenicity was observed in male and female rats at promethazine hydrochloride oral doses up to 33 mg/kg/day for 5 days/week (approximately equivalent to 10 times the MRHD on a mg/m 2 basis). No evidence of tumorigenicity was observed in male and female mice at promethazine hydrochloride oral doses up to 45 and 15 mg/kg/day for 5 days/week (approximately equivalent to 7 and 2 times the MRHD on a mg/m 2 basis, respectively). Promethazine hydrochloride was not mutagenic in the in vitro bacterial reverse mutation assay or clastogenic in the in vitro Chinese hamster ovary (CHO) cell chromosomal aberration assay. Fertility studies with promethazine have not been conducted. Phenylephrine Carcinogenicity studies were conducted with phenylephrine hydrochloride. Two-year studies in F344/N rats and B6C3F1 mice were conducted to assess the carcinogenic potential of phenylephrine hydrochloride. No evidence of tumorigenicity was observed in male and female rats at phenylephrine hydrochloride dietary doses up to 50 mg/kg/day (approximately equivalent to 20 times the MRHD on a mg/m 2 basis). No evidence of tumorigenicity was observed in male and female mice at phenylephrine hydrochloride dietary doses up to 270 mg/kg/day (approximately equivalent to 55 times the MRHD on a mg/m 2 basis). Phenylephrine hydrochloride tested negative in the in vitro bacterial reverse mutation assay, in vitro Chinese hamster ovary (CHO) cell chromosomal aberrations assay, and in vivo rat micronucleus assay. Phenylephrine hydrochloride was equivocal in the in vitro mouse lymphoma assay without metabolic activation; however, a test with metabolic activation was not performed. Fertility studies with phenylephrine have not been conducted.

ANDA040660

Promethazine VC with Codeine Oral Solution

Promethazine and Phenylephrine Hydrochloride and Codeine Phosphate

0121-0925

HUMAN PRESCRIPTION DRUG

ORAL

Package Label - One Pint (473 mL) NDC 0121-0925-16 PROMETHAZINE VC WITH CODEINE ORAL SOLUTION CV (PROMETHAZINE PHENYLEPHRINE HYDROCHLORIDE AND CODEINE PHOSPHATE ORAL SOLUTION) EACH 5 mL (ONE TEASPOONFUL) CONTAINS: Codeine Phosphate..................10 mg Promethazine Hydrochloride.....6.25 mg Phenylephrine Hydrochlord...........5 mg Alcohol..................................7% Dispense the accompanying Medication Guide to each patient. Rx ONLY ONE PINT (473 mL) USUAL DOSAGE : See accompanying package insert. Dispense in a tight, light-resistant container with a child-resitant closure as defined in the USP. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Keep tightly closed. Protect from light. X0925160820 R08/20 Package Label - One Pint (473 mL)

Boxed Warning 8/2017 and 06/2018 Indications and Usage ( 1 ) 06/2018 Dosage and Administration ( 2.1 , 2.3 ) 06/2018 Dosage and Administration, Children under 12 years ( 2.2 ) Removed 08/2017 Dosage and Administration, Children under 18 years ( 2.2 ) Removed 06/2018 Contraindications ( 4 ) 08/2017 and 06/2018 Warnings and Precautions ( 5.3 , 5.4 ) 08/2017 Warnings and Precautions ( 5.1 , 5.2 , 5.3 , 5.4 , 5.5 , 5.6 , 5.7 , 5.9 , 5.11 , 5.13 , 5.17 , 5.19 , 5.20 , 5.21 ) 06/2018

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling ( Medication Guide ). Addiction, Abuse, and Misuse Inform patients that the use of Promethazine VC with Codeine Oral Solution, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death [ see Warnings and Precautions ( 5.1 ) ]. Instruct patients not to share Promethazine VC with Codeine Oral Solution with others and to take steps to protect Promethazine VC with Codeine Oral Solution from theft or misuse. Important Dosing and Administration Instructions Instruct patients how to measure and take the correct dose of Promethazine VC with Codeine Oral Solution. Advise patients to measure Promethazine VC with Codeine Oral Solution with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage. Advise patients to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose [ see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.7 ) ]. Advise patients not to increase the dose or dosing frequency of Promethazine VC with Codeine Oral Solution because serious adverse events such as respiratory depression may occur with overdosage [ see Warnings and Precautions ( 5.2 ) and Overdosage ( 10 ) ]. Life-Threatening Respiratory Depression Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting Promethazine VC with Codeine Oral Solution and that it can occur even at recommended dosages [ see Warnings and Precautions ( 5.2 ) ]. Advise patients how to recognize respiratory depression and to seek medical attention if breathing difficulties develop. Accidental Ingestion Inform patients that accidental ingestion, especially by children, may result in respiratory depression or death [ see Warnings and Precautions ( 5.2 ) ]. Instruct patients to take steps to store Promethazine VC with Codeine Oral Solution securely and to properly dispose of unused Promethazine VC with Codeine Oral Solution in accordance with the local state guidelines and/or regulations. Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-Threatening Respiratory Depression in Children Advise caregivers that Promethazine VC with Codeine Oral Solution is not indicated for pediatric patients under 18 years of age, and is contraindicated in all children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. Activities Requiring Mental Alertness Advise patients to avoid engaging in hazardous tasks that require mental alertness and motor coordination such as operating machinery or driving a motor vehicle as Promethazine VC with Codeine Oral Solution may produce marked drowsiness [ see Warnings and Precautions ( 5.8 ) ]. Interactions with Benzodiazepines and Other Central Nervous System Depressants, Including Alcohol Inform patients and caregivers that potentially fatal additive effects may occur if Promethazine VC with Codeine Oral Solution is used with benzodiazepines or other CNS depressants, including alcohol. Advise patients to avoid concomitant use of Promethazine VC with Codeine Oral Solution with benzodiazepines or other CNS depressants and to not use alcohol while taking Promethazine VC with Codeine Oral Solution [ see Warnings and Precautions ( 5.10 ) and Drug Interactions ( 7.4 ) ]. Constipation Advise patients of the potential for severe constipation [ see Warnings and Precautions ( 5.11 ) and Adverse Reactions ( 6 ) ]. Cardiovascular and CNS Effects Inform patients that the phenylephrine contained in Promethazine VC with Codeine Oral Solution can produce cardiovascular and central nervous system effects in some patients such as, insomnia, dizziness, weakness, tremor, transient elevations in blood pressure, or arrhythmias. Anaphylaxis Inform patients that anaphylaxis has been reported with ingredients contained in Promethazine VC with Codeine Oral Solution. Advise patients how to recognize such a reaction and when to seek medical attention [ see Contraindications ( 4 ) and Adverse Reactions ( 6 ) ]. MAOI Interaction Inform patients not to take Promethazine VC with Codeine Oral Solution while using or within 14 days of stopping any drugs that inhibit monoamine oxidase. Patients should not start MAOIs while taking Promethazine VC with Codeine Oral Solution [ see Contraindications ( 4 ), Warnings and Precautions ( 5.17 ), and Drug Interactions ( 7.6 ) ]. Hypotension Inform patients that Promethazine VC with Codeine Oral Solution may cause orthostatic hypotension and syncope. Instruct patients how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (eg, sit or lie down, carefully rise from a sitting or lying position) [ see Warnings and Precautions ( 5.19 ) ]. Pregnancy Advise patients that use of Promethazine VC with Codeine Oral Solution is not recommended during pregnancy [ see Use in Specific Populations ( 8.1 ) ]. Neonatal Opioid Withdrawal Syndrome Inform female patients of reproductive potential that use of Promethazine VC with Codeine Oral Solution during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated [ see Warnings and Precautions ( 5.20 ) and Use in Specific Populations (8.1) ]. Embryo-Fetal Toxicity Inform female patients of reproductive potential that Promethazine VC with Codeine Oral Solution can cause fetal harm and to inform their healthcare provider of a known or suspected pregnancy [ see Use in Specific Populations ( 8.1 ) ]. Lactation Advise women that breastfeeding is not recommended during treatment with Promethazine VC with Codeine Oral Solution [ see Use in Specific Populations ( 8.2 ) ]. Infertility Inform patients that chronic use of opioids, such as codeine, a component of Promethazine VC with Codeine Oral Solution, may cause reduced fertility. It is not known whether these effects on fertility are reversible [ see Use in Specific Populations ( 8.3 ) ]. Adrenal Insufficiency Inform patients that Promethazine VC with Codeine Oral Solution could cause adrenal insufficiency, a potentially life-threatening condition. Adrenal insufficiency may present with non-specific symptoms and signs such as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. Advise patients to seek medical attention if they experience a constellation of these symptoms [ see Warnings and Precautions ( 5.21 ) ]. Serotonin Syndrome Inform patients that Promethazine VC with Codeine Oral Solution could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their physicians if they are taking, or plan to take serotonergic medications [ see Adverse Reactions ( 6 ) and Drug Interactions ( 7.5 ) ]. Disposal of Unused Promethazine VC with Codeine Oral Solution Advise patients to properly dispose of unused Promethazine VC with Codeine Oral Solution. Advise patients to throw the drug in the household trash following these steps: 1) Remove them from their original containers and mix them with an undesirable substance, such as used coffee grounds or kitty litter (this makes the drug less appealing to children and pets, and unrecognizable to people who may intentionally go through the trash seeking drugs). 2) Place the mixture in a sealable bag, empty can, or other container to prevent the drug from leaking or breaking out of a garbage bag, or to dispose of in accordance with local state guidelines and/or regulations. DISTRIBUTED BY Pharmaceutical Associates, Inc. Greenville, SC 29605 www.paipharma.com R08/20

MEDICATION GUIDE PROMETHAZINE (proe METH a zeen) VC WITH CODEINE (KOE deen) ORAL SOLUTION (promethazine hydrochloride, phenylephrine hydrochloride, and codeine phosphate) oral solution, CV What is the most important information I should know about PROMETHAZINE VC WITH CODEINE ORAL SOLUTION? PROMETHAZINE VC WITH CODEINE ORAL SOLUTION is not for children under 18 years of age. PROMETHAZINE VC WITH CODEINE ORAL SOLUTION can cause serious side effects, including: Addiction, abuse and misuse . Taking PROMETHAZINE VC WITH CODEINE ORAL SOLUTION or other medicines that contain an opioid can cause addiction, abuse, and misuse, which can lead to overdose and death. This can happen even if you take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION exactly as prescribed by your healthcare provider. Your risk of addiction, abuse, and misuse is increased if you or a family member has a history of drug or alcohol abuse or addiction, or mental health problems. Do not share your PROMETHAZINE VC WITH CODEINE ORAL SOLUTION with other people. Keep PROMETHAZINE VC WITH CODEINE ORAL SOLUTION in a safe place away from children. Life-threatening breathing problems (respiratory depression). PROMETHAZINE VC WITH CODEINE ORAL SOLUTION can cause breathing problems (respiratory depression) that can happen at any time during treatment and can lead to death. Your risk of breathing problems is greatest when you first start taking PROMETHAZINE VC WITH CODEINE ORAL SOLUTION, are taking other medicines that can cause breathing problems, have certain lung problems, are elderly or have certain other health problems. Children are at higher risk for respiratory depression . Breathing problems can happen even if you take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION exactly as prescribed by your healthcare provider. Call your healthcare provider or get emergency medical help right away if anyone taking PROMETHAZINE VC WITH CODEINE ORAL SOLUTION, or your breastfeeding baby, has any of the symptoms below: increased sleepiness shallow breathing confusion limpness difficulty breathing Keep PROMETHAZINE VC WITH CODEINE ORAL SOLUTION in a safe place away from children . Accidental use of even 1 dose of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION, especially by a child, is a medical emergency and can cause breathing problems (respiratory depression) which can lead to death. If a child accidentally takes PROMETHAZINE VC WITH CODEINE ORAL SOLUTION, get emergency help right away. Overdose and death due to medicine dosing errors . Overdose and death can happen if you measure the wrong dose of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. Always use an accurate milliliter (mL) measuring device to measure the correct amount of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. Do not use a household teaspoon to measure your medicine. You may accidentally take too much. You can ask your pharmacist for the measuring device you should use and how to measure the correct dose. Breathing problems (respiratory depression) that can lead to death and opioid withdrawal can happen if you start taking or stop taking other medicines while taking PROMETHAZINE VC WITH CODEINE ORAL SOLUTION, including: certain antibiotics certain medicines to treat a fungal infection certain medicines to treat Human Immunodeficiency Virus (HIV)-1 infection, Acquired Immune Deficiency Syndrome (AIDS), or Hepatitis C rifampin carbamazepine phenytoin Severe drowsiness, breathing problems (respiratory depression), coma, and death can happen in adults and children who take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION with benzodiazepines, or other central nervous system depressants, including alcohol. Do not take any benzodiazepines or medicines that can cause drowsiness or sleepiness during treatment with PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. Ask your healthcare provider for a list of these medicines if you are not sure. Do not drink alcohol during treatment with PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. Opioid withdrawal in a newborn . Use of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated. You should not take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION if you are pregnant. Tell your healthcare provider right away if you are pregnant or think you may be pregnant. What is PROMETHAZINE VC WITH CODEINE ORAL SOLUTION? PROMETHAZINE VC WITH CODEINE ORAL SOLUTION is a prescription medicine used in adults to temporarily treat cough and upper respiratory symptoms, including a stuffy nose (nasal congestion), that you can have with allergies or a common cold. PROMETHAZINE VC WITH CODEINE ORAL SOLUTION contains 3 medicines, promethazine, phenylephrine, and codeine. PROMETHAZINE VC WITH CODEINE ORAL SOLUTION is an antihistamine. Phenylephrine is a decongestant. Codeine is an opioid (narcotic) cough suppressant. PROMETHAZINE VC WITH CODEINE ORAL SOLUTION is a federal controlled substance (C V) because it contains codeine that can be abused or lead to dependence. Keep PROMETHAZINE VC WITH CODEINE ORAL SOLUTION in a safe place to prevent misuse and abuse. Selling or giving away PROMETHAZINE VC WITH CODEINE ORAL SOLUTION may harm others, and is against the law. Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines or street drugs. Who should not take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION? PROMETHAZINE VC WITH CODEINE ORAL SOLUTION is not for children under 18 years of age . See “ What is the most important information I should know about PROMETHAZINE VC WITH CODEINE ORAL SOLUTION?” Do not take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION if you : have severe breathing problems (respiratory depression). See “ What is the most important information I should know about PROMETHAZINE VC WITH CODEINE ORAL SOLUTION?” have a blockage (obstruction) in your bowel such as a paralytic ileus. take a medicine called a monoamine oxidase inhibitor (MAOI). Do not take an MAOI within 14 days after you stop taking PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. Do not start taking PROMETHAZINE VC WITH CODEINE ORAL SOLUTION if you stopped taking an MAOI in the last 14 days. have a type of glaucoma called “narrow angle glaucoma”. have problems with your urinary tract or difficulty urinating (urinary retention). have severe high blood pressure (hypertension), certain heart problems (severe coronary artery disease), or narrowing of blood vessels to your legs or arms (peripheral vascular insufficiency). are allergic to promethazine, phenylephrine, codeine, or any of the ingredients in PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. See the end of this Medication Guide for a complete list of ingredients in PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. You may have an increased risk of an allergic reaction to PROMETHAZINE VC WITH CODEINE ORAL SOLUTION if you are allergic to certain other opioid medicines. Ask your healthcare provider if you have any questions about this information. Before you take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION, tell your healthcare provider about all of your medical conditions, including if you: have a drug addiction have lung or breathing problems have a fever and are coughing up mucus have had a recent head injury have had brain tumor or other brain problems have or have had seizures have pain in your stomach-area (abdomen) have constipation or other bowel problems have bile duct or pancreas problems have glaucoma (increased pressure in eyes) have prostate problems have kidney or liver problems have problems with your urinary tract or difficulty urinating have high blood pressure have heart or blood vessel (cardiovascular) problems including peripheral vascular insufficiency have uncontrolled spasms of your face, neck or muscles of your body, arms and legs (dystonia) have a history of neuroleptic malignant syndrome (NMS) have blood disorders including low white blood cells have low blood pressure (hypotension) have adrenal gland problems plan to have surgery are pregnant or plan to become pregnant. PROMETHAZINE VC WITH CODEINE ORAL SOLUTION can harm your unborn baby. See “ What is the most important information I should know about PROMETHAZINE VC WITH CODEINE ORAL SOLUTION?” are breastfeeding or plan to breastfeed. Codeine passes into your breast milk and can cause serious side effects in your baby including increased sleepiness, breathing problems (respiratory depression), and death. It is not known if promethazine or phenylephrine can pass into your breast milk. You and your healthcare provider should decide if you will take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION or breastfeed. You should not do both. See “ What should I avoid while taking PROMETHAZINE VC WITH CODEINE ORAL SOLUTION?” plan to have children. PROMETHAZINE VC WITH CODEINE ORAL SOLUTION may affect the ability to have a child in females and males (fertility problems). It is not known if these fertility problems will be reversible, even after you stop taking PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PROMETHAZINE VC WITH CODEINE ORAL SOLUTION with certain other medicines can cause side effects or affect how well PROMETHAZINE VC WITH CODEINE ORAL SOLUTION or the other medicines work. Do not start or stop taking other medicines without talking to your healthcare provider. Especially tell your healthcare provider if you: See “ What is the most important information I should know about PROMETHAZINE VC WITH CODEINE ORAL SOLUTION?” take pain medicines such as opioids (narcotics). take cold or allergy medicines that contain antihistamines or cough suppressants. drink alcohol. take muscles relaxants. take certain medicines used to treat mood, anxiety, psychotic or thought disorders, or depression, including monoamine oxidase inhibitors (MAOIs), tricyclics, selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), or antipsychotics. take medicines to lower your blood pressure. take water pills (diuretics). take medicines called “anticholinergics” used to treat asthma, chronic obstructive pulmonary disease (COPD), or stomach problems. take medicines called “sympathomimetics” used to treat asthma, chronic obstructive pulmonary disease (COPD), or low blood pressure. take ergot containing medicines used to treat severe headaches or migraines. take medicines called alpha and beta blockers. Ask your healthcare provider if you are not sure if you take one of these medicines. How should I take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION? See “What is the most important information I should know about PROMETHAZINE VC WITH CODEINE ORAL SOLUTION?” Take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION exactly as your healthcare provider tells you to take it. Do not change your dose without talking to your healthcare provider. Take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION by mouth only. Do not take more than 30 mL of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION in 24 hours. Take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION using an accurate milliliter (mL) measuring device. If you do not have one, ask your pharmacist to give you a measuring device to measure the correct amount of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. Do not use a household teaspoon to measure your medicine. You may accidently take too much. Do not overfill the measuring device. Rinse your measuring device with water after each use. If you take too much PROMETHAZINE VC WITH CODEINE ORAL SOLUTION, call your healthcare provider or go to the nearest hospital emergency room right away. Tell your healthcare provider if your cough does not get better within 5 days of treatment with PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. What should I avoid while taking PROMETHAZINE VC WITH CODEINE ORAL SOLUTION? Avoid driving a car or operating machinery during treatment with PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. PROMETHAZINE VC WITH CODEINE ORAL SOLUTION can cause you to be drowsy, slow your thinking and motor skills, and affect your vision. Do not drink alcohol during treatment with PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. Drinking alcohol with PROMETHAZINE VC WITH CODEINE ORAL SOLUTION can increase your chances of having serious side effects, accidental overdose, and cause death. Avoid the use of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION if you: are pregnant. Use of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated. Tell your healthcare provider right away if you are pregnant or think you may be pregnant. are breastfeeding. Use of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION while breastfeeding can cause severe breathing problems (respiratory depression) in your breastfed infant that could be life-threatening. What are the possible side effects of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION? PROMETHAZINE VC WITH CODEINE ORAL SOLUTION may cause serious side effects, including: See “ What is the most important information I should know about PROMETHAZINE VC WITH CODEINE ORAL SOLUTION ?” Bowel problems including severe constipation or stomach pain . See “ Who should not take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION?” Increased pressure in your head (increased intracranial pressure). Avoid the use of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION if you have a head injury or have been told that you have changes in the tissue of your brain (brain lesions) or increased pressure in your head. Neuroleptic malignant syndrome (NMS) which can lead to death . Tell you healthcare provider right away if you have any of the following symptoms of NMS: high fever stiff muscles confusion sweating changes in pulse, heart rate, or blood pressure Uncontrolled spasms of your face and neck muscles, or muscles of your body, arms, and legs (dystonia) . These muscle spasms can cause abnormal movements and body positions, and speech problems. These spasms may happen after one dose of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. Tell your healthcare provider if you have any of these symptoms. Heart and blood vessel (cardiovascular) and central nervous system (CNS) effects. Cardiovascular and CNS effects can happen in some people during treatment with PROMETHAZINE VC WITH CODEINE ORAL SOLUTION, including trouble sleeping (insomnia), dizziness, weakness, tremors, temporary increases in blood pressure, and abnormal heart beats (arrhythmias). Call your healthcare provider right away if you have any of these symptoms. Increased risk of seizures in people with seizure disorders . If you have a seizure disorder, PROMETHAZINE VC WITH CODEINE ORAL SOLUTION may increase how often you have seizures. Low blood pressure . A sudden drop in blood pressure can happen in some people during treatment with PROMETHAZINE VC WITH CODEINE ORAL SOLUTION and this may cause you to feel dizzy, faint, lightheaded, or weak, especially when you stand up (orthostatic hypotension). Your risk of having this problem may be increased if you take PROMETHAZINE VC WITH CODEINE ORAL SOLUTION with certain other medicines that lower blood pressure. If you have any of these symptoms while taking PROMETHAZINE VC WITH CODEINE ORAL SOLUTION, sit or lie down. Do not change your body position too fast. Get up slowly from sitting or lying down. Adrenal gland problems . PROMETHAZINE VC WITH CODEINE ORAL SOLUTION can cause serious and life-threatening adrenal gland problems. Your healthcare provider may do blood tests to check for adrenal gland problems. Call your healthcare provider right away if you have any of these symptoms nausea vomiting not wanting to eat (anorexia) fatigue weakness dizziness low blood pressure Changes in laboratory blood levels, including high blood sugar and false pregnancy test reading. The most common side effects of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION include : sleepiness confusion coordination problems decrease in mental and physical performance lack of energy lightheadedness dizziness headache irritability anxiety restlessness nervousness tremor dry mouth difficulty urinating sweating shortness of breath nausea vomiting constipation high blood pressure fast or irregular heart beat These are not all the possible side effects of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store PROMETHAZINE VC WITH CODEINE ORAL SOLUTION? Store PROMETHAZINE VC WITH CODEINE ORAL SOLUTION at room temperature between 68°F to 77°F (20°C to 25°C). Store PROMETHAZINE VC WITH CODEINE ORAL SOLUTION in a tightly closed container, in a dry, cool place away from heat or direct sunlight. Keep PROMETHAZINE VC WITH CODEINE ORAL SOLUTION and all medicines out of the reach of children. How should I dispose of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION? Remove unused PROMETHAZINE VC WITH CODEINE ORAL SOLUTION from the container and mix it with an undesirable, non-toxic substance such as cat litter or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw it away in the household trash. You can also follow your state or local guidelines on how to safely throw away PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. General information about the safe and effective use of PROMETHAZINE VC WITH CODEINE ORAL SOLUTION. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use PROMETHAZINE VC WITH CODEINE ORAL SOLUTION for a condition for which it was not prescribed. Do not give PROMETHAZINE VC WITH CODEINE ORAL SOLUTION to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about PROMETHAZINE VC WITH CODEINE ORAL SOLUTION that is written for health professionals. What are the ingredients in PROMETHAZINE VC WITH CODEINE ORAL SOLUTION? Active ingredients: codeine phosphate, promethazine hydrochloride, and phenylephrine hydrochloride Inactive ingredients : Ascorbic acid, citric acid, D&C Red #33, FD&C Yellow #6, menthol, methylparaben, propylene glycol, propylparaben, purified water, saccharin sodium, sodium benzoate, sodium citrate, strawberry flavor and sucrose. Distributed by: Pharmaceutical Associates, Inc. Greenville, SC 29605. For more information, call 1-800-845-8210. This Medication Guide has been approved by the U.S. Food and Drug Administration Revised:08/2020

8.5 Geriatric Use Clinical studies have not been conducted with Promethazine VC with Codeine Oral Solution in geriatric populations. Use caution when considering the use of Promethazine VC with Codeine Oral Solution in patients 65 years of age or older. Elderly patients may have increased sensitivity to codeine; greater frequency of decreased hepatic, renal, or cardiac function; or concomitant disease or other drug therapy [see Warnings and Precautions ( 5.6 ) ]. Respiratory depression is the chief risk for elderly patients treated with opioids, including Promethazine VC with Codeine Oral Solution. Respiratory depression has occurred after large initial doses of opioids were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration [see Warnings and Precautions ( 5.6 , 5.10 ) ]. Codeine is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, monitor these patients closely for respiratory depression, sedation, and hypotension.

8.4 Pediatric Use Promethazine VC with Codeine Oral Solution is not indicated for use in patients younger than 18 years of age because the benefits of symptomatic treatment of cough associated with allergies or the common cold do not outweigh the risks for use of codeine in these patients [ see Indications ( 1 ) and Warnings and Precautions ( 5.5 ) ]. Life-threatening respiratory depression and death have occurred in children who received codeine [see Warnings and Precautions ( 5.2 ) ]. In most of the reported cases, these events followed tonsillectomy and/or adenoidectomy, and many of the children had evidence of being ultra-rapid metabolizers of codeine (ie, multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). Children with sleep apnea may be particularly sensitive to the respiratory depressant effects of codeine. Life-threatening respiratory depression and death have also occurred in children who received promethazine [see Warnings and Precautions ( 5.4 ) ]. Because of the risk of life-threatening respiratory depression and death: Promethazine VC with Codeine Oral Solution is contraindicated for all children younger than 12 years of age [see Contraindications ( 4 ) ]. Promethazine VC with Codeine Oral Solution is contraindicated for post-operative management in pediatric patients younger than 18 years of age following tonsillectomy and/or adenoidectomy [see Contraindications ( 4 ) ]. Avoid the use of Promethazine VC with Codeine Oral Solution in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine unless the benefits outweigh the risks. Risk factors include conditions associated with hypoventilation, such as postoperative status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, and concomitant use of other medications that cause respiratory depression [see Warnings and Precautions ( 5.3 , 5.6 ) ].

8.1 Pregnancy Risk Summary Promethazine VC with Codeine Oral Solution is not recommended for use in pregnant women, including during or immediately prior to labor. Prolonged use of opioids during pregnancy may cause neonatal opioid withdrawal syndrome [ see Warnings and Precautions ( 5.20 ), Clinical Considerations ]. There are no available data with Promethazine VC with Codeine Oral Solution use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Published studies with codeine have reported inconsistent findings and have important methodological limitations ( see Data ). There are reports of respiratory depression when codeine is used during labor and delivery ( see Clinical Considerations ). Reproductive toxicity studies have not been conducted with Promethazine VC with Codeine Oral Solution; however, studies are available with individual active ingredients ( see Data ). In animal reproduction studies, codeine administered by the oral route to pregnant rats during the period of organogenesis increased resorptions and decreased fetal weights at a dose approximately 26 times the maximum recommended human dose (MRHD) in the presence of maternal toxicity ( see Data ). For pregnant mice and rats that received promethazine at doses 0.15 to 3 times the MRHD, during various periods of gestation, there were findings of increased fetal resorptions and skeletal fragility, decreased pup weight, and developmental delays of pups ( see Data ). In studies with normotensive pregnant rabbits, which received phenylephrine during the period of organogenesis or later, there were findings of increased fetal lethality, adverse placental effects, and possible teratogenic effects at subcutaneous doses approximately 0.8 times the MRHD on a mg/m2 basis. Premature labor was also observed when treatment was initiated during the second trimester or later ( see Data ). Based on the animal data, advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [ see Warnings and Precautions ( 5.20 )]. Maternal use of phenylephrine can cause fetal tachycardia. Labor or Delivery Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. Opioids, including Promethazine VC with Codeine Oral Solution, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioids during labor for signs of excess sedation and respiratory depression. Data Human Data Published data from case-control and observational studies on codeine use during pregnancy are inconsistent in their findings. Some studies of codeine exposure showed an increased risk of overall congenital malformations while others did not. An increased risk of specific malformations with codeine exposure such as respiratory malformations, spina bifida and congenital heart defects were reported in some studies. The majority of studies examining the use of phenylephrine and promethazine in pregnancy did not find an association with an increased risk of congenital anomalies. In the few studies reporting an association, no consistent pattern of malformations was noted. Most of the studies, both positive and negative, were limited by small sample size, recall bias and lack of information regarding dose and timing of exposure. Animal Data Reproductive toxicity studies have not been conducted with Promethazine VC with Codeine Oral Solution; however, studies are available with individual active ingredients. Codeine In an embryofetal development study in pregnant rats dosed throughout the period of organogenesis, codeine increased resorptions and decreased fetal weights at a dose approximately 26 times the MRHD (on a mg/m 2 basis with a maternal oral dose of 120 mg/kg/day); however, these effects occurred in the presence of maternal toxicity. In embryofetal development studies with pregnant rabbits and mice dosed throughout the period of organogenesis, codeine produced no adverse developmental effects at doses approximately 13 and 66 times, respectively, the MRHD (on a mg/m 2 basis with maternal oral doses of 30 mg/kg/day in rabbits and 600 mg/kg/day in mice). Promethazine In pregnant mice dosed during the period of implantation from gestation days 1 to 5, promethazine increased resorption at doses approximately 0.2 times the MRHD (on a mg/m2 basis with maternal intraperitoneal and subcutaneous doses up to 1 mg/kg/day). In pregnant rats dosed during the period of organogenesis from gestation days 5 to 16, promethazine hydrochloride induced complete resorption at doses approximately 6 times the MRHD (on a mg/m 2 basis with maternal oral doses up to 20 mg/kg/day). In pregnant rats dosed during the period of organogenesis from gestation days 7 to 13, promethazine resulted in skeletal fragility of pups at doses approximately 3 times the MRHD (on a mg/m 2 basis with maternal oral doses up to 10 mg/kg/day). In pregnant rats dosed during the period of organogenesis from gestation days 10 to 12, promethazine resulted in decreased weight and delays in initial occurrence of behavioral/reflex of pups at doses approximately 3 times the MRHD (on a mg/m 2 basis with maternal oral doses up to 10 mg/kg/day). The relevance of these findings to humans is unclear. Phenylephrine In studies with normotensive pregnant rabbits, which received phenylephrine during the period of organogenesis or later, there were findings of fetal deaths, adverse histopathology findings in the placenta (necrosis, calcification and thickened vascular walls with narrowed lumen), and possible teratogenic effects (one incidence of clubbed feet, partial development of the intestine) at doses approximately 0.8 times the MRHD (on a mg/m 2 basis with a maternal subcutaneous dose of 1 mg/kg/day). Premature labor was also observed when treatment was initiated during the second trimester or later. Mean percentage of implantations in rabbits was decreased by injection of phenylephrine.

8 USE IN SPECIFIC POPULATIONS Pregnancy : Avoid use in pregnant women. May cause fetal harm. ( 8.1 ) Lactation : Breastfeeding not recommended. ( 8.2 ) Renal Impairment : Use with caution in patients with severe renal impairment. ( 8.6 ) Hepatic Impairment : Use with caution in patients with severe hepatic impairment. ( 8.7 ) 8.1 Pregnancy Risk Summary Promethazine VC with Codeine Oral Solution is not recommended for use in pregnant women, including during or immediately prior to labor. Prolonged use of opioids during pregnancy may cause neonatal opioid withdrawal syndrome [ see Warnings and Precautions ( 5.20 ), Clinical Considerations ]. There are no available data with Promethazine VC with Codeine Oral Solution use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Published studies with codeine have reported inconsistent findings and have important methodological limitations ( see Data ). There are reports of respiratory depression when codeine is used during labor and delivery ( see Clinical Considerations ). Reproductive toxicity studies have not been conducted with Promethazine VC with Codeine Oral Solution; however, studies are available with individual active ingredients ( see Data ). In animal reproduction studies, codeine administered by the oral route to pregnant rats during the period of organogenesis increased resorptions and decreased fetal weights at a dose approximately 26 times the maximum recommended human dose (MRHD) in the presence of maternal toxicity ( see Data ). For pregnant mice and rats that received promethazine at doses 0.15 to 3 times the MRHD, during various periods of gestation, there were findings of increased fetal resorptions and skeletal fragility, decreased pup weight, and developmental delays of pups ( see Data ). In studies with normotensive pregnant rabbits, which received phenylephrine during the period of organogenesis or later, there were findings of increased fetal lethality, adverse placental effects, and possible teratogenic effects at subcutaneous doses approximately 0.8 times the MRHD on a mg/m2 basis. Premature labor was also observed when treatment was initiated during the second trimester or later ( see Data ). Based on the animal data, advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [ see Warnings and Precautions ( 5.20 )]. Maternal use of phenylephrine can cause fetal tachycardia. Labor or Delivery Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. Opioids, including Promethazine VC with Codeine Oral Solution, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioids during labor for signs of excess sedation and respiratory depression. Data Human Data Published data from case-control and observational studies on codeine use during pregnancy are inconsistent in their findings. Some studies of codeine exposure showed an increased risk of overall congenital malformations while others did not. An increased risk of specific malformations with codeine exposure such as respiratory malformations, spina bifida and congenital heart defects were reported in some studies. The majority of studies examining the use of phenylephrine and promethazine in pregnancy did not find an association with an increased risk of congenital anomalies. In the few studies reporting an association, no consistent pattern of malformations was noted. Most of the studies, both positive and negative, were limited by small sample size, recall bias and lack of information regarding dose and timing of exposure. Animal Data Reproductive toxicity studies have not been conducted with Promethazine VC with Codeine Oral Solution; however, studies are available with individual active ingredients. Codeine In an embryofetal development study in pregnant rats dosed throughout the period of organogenesis, codeine increased resorptions and decreased fetal weights at a dose approximately 26 times the MRHD (on a mg/m 2 basis with a maternal oral dose of 120 mg/kg/day); however, these effects occurred in the presence of maternal toxicity. In embryofetal development studies with pregnant rabbits and mice dosed throughout the period of organogenesis, codeine produced no adverse developmental effects at doses approximately 13 and 66 times, respectively, the MRHD (on a mg/m 2 basis with maternal oral doses of 30 mg/kg/day in rabbits and 600 mg/kg/day in mice). Promethazine In pregnant mice dosed during the period of implantation from gestation days 1 to 5, promethazine increased resorption at doses approximately 0.2 times the MRHD (on a mg/m2 basis with maternal intraperitoneal and subcutaneous doses up to 1 mg/kg/day). In pregnant rats dosed during the period of organogenesis from gestation days 5 to 16, promethazine hydrochloride induced complete resorption at doses approximately 6 times the MRHD (on a mg/m 2 basis with maternal oral doses up to 20 mg/kg/day). In pregnant rats dosed during the period of organogenesis from gestation days 7 to 13, promethazine resulted in skeletal fragility of pups at doses approximately 3 times the MRHD (on a mg/m 2 basis with maternal oral doses up to 10 mg/kg/day). In pregnant rats dosed during the period of organogenesis from gestation days 10 to 12, promethazine resulted in decreased weight and delays in initial occurrence of behavioral/reflex of pups at doses approximately 3 times the MRHD (on a mg/m 2 basis with maternal oral doses up to 10 mg/kg/day). The relevance of these findings to humans is unclear. Phenylephrine In studies with normotensive pregnant rabbits, which received phenylephrine during the period of organogenesis or later, there were findings of fetal deaths, adverse histopathology findings in the placenta (necrosis, calcification and thickened vascular walls with narrowed lumen), and possible teratogenic effects (one incidence of clubbed feet, partial development of the intestine) at doses approximately 0.8 times the MRHD (on a mg/m 2 basis with a maternal subcutaneous dose of 1 mg/kg/day). Premature labor was also observed when treatment was initiated during the second trimester or later. Mean percentage of implantations in rabbits was decreased by injection of phenylephrine. 8.2 Lactation Risk Summary Because of the potential for serious adverse reactions, including excess sedation, respiratory depression, and death in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with Promethazine VC with Codeine Oral Solution [see Warnings and Precautions ( 5.3 ) ]. There are no data on the presence of Promethazine VC with Codeine Oral Solution in human milk, the effects of Promethazine VC with Codeine Oral Solution on the breastfed infant, or the effects of Promethazine VC with Codeine Oral Solution on milk production; however, data are available with codeine and promethazine. Codeine Codeine and its active metabolite, morphine, are present in human milk. There are published studies and cases that have reported excessive sedation, respiratory depression and death (in one infant) in infants exposed to codeine via breast milk. Women who are ultra-rapid metabolizers of codeine achieve higher than expected serum levels of morphine, potentially leading to higher levels of morphine in breast milk that can be dangerous in their breastfed infants. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. There is no information on the effects of the codeine on milk production. Promethazine There are no data on the presence of promethazine in human milk. However, direct oral administration of promethazine has been associated with respiratory depression, including fatalities, in pediatric patients [ see Warnings and Precautions ( 5.4 ) ]. Promethazine has been shown to decrease basal prolactin levels in non-nursing women, and therefore may affect milk production. Phenylephrine There are no data on the presence of phenylephrine in human milk or on its effects on the breastfed infant. Phenylephrine is known to be poorly absorbed orally. Animal data indicate that phenylephrine can decrease milk production and pharmacologically similar vasoconstrictors, such as pseudoephedrine, decrease milk production in lactating women after oral use. Clinical Considerations Infants exposed to Promethazine VC with Codeine Oral Solution through breast milk should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid is stopped, or when breastfeeding is stopped. 8.3 Females and Males of Reproductive Potential Infertility Chronic use of opioids, such as codeine, a component of Promethazine VC with Codeine Oral Solution, may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible [see Adverse Reactions ( 6 ) and Clinical Pharmacology ( 12.2 ) ]. 8.4 Pediatric Use Promethazine VC with Codeine Oral Solution is not indicated for use in patients younger than 18 years of age because the benefits of symptomatic treatment of cough associated with allergies or the common cold do not outweigh the risks for use of codeine in these patients [ see Indications ( 1 ) and Warnings and Precautions ( 5.5 ) ]. Life-threatening respiratory depression and death have occurred in children who received codeine [see Warnings and Precautions ( 5.2 ) ]. In most of the reported cases, these events followed tonsillectomy and/or adenoidectomy, and many of the children had evidence of being ultra-rapid metabolizers of codeine (ie, multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). Children with sleep apnea may be particularly sensitive to the respiratory depressant effects of codeine. Life-threatening respiratory depression and death have also occurred in children who received promethazine [see Warnings and Precautions ( 5.4 ) ]. Because of the risk of life-threatening respiratory depression and death: Promethazine VC with Codeine Oral Solution is contraindicated for all children younger than 12 years of age [see Contraindications ( 4 ) ]. Promethazine VC with Codeine Oral Solution is contraindicated for post-operative management in pediatric patients younger than 18 years of age following tonsillectomy and/or adenoidectomy [see Contraindications ( 4 ) ]. Avoid the use of Promethazine VC with Codeine Oral Solution in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine unless the benefits outweigh the risks. Risk factors include conditions associated with hypoventilation, such as postoperative status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, and concomitant use of other medications that cause respiratory depression [see Warnings and Precautions ( 5.3 , 5.6 ) ]. 8.5 Geriatric Use Clinical studies have not been conducted with Promethazine VC with Codeine Oral Solution in geriatric populations. Use caution when considering the use of Promethazine VC with Codeine Oral Solution in patients 65 years of age or older. Elderly patients may have increased sensitivity to codeine; greater frequency of decreased hepatic, renal, or cardiac function; or concomitant disease or other drug therapy [see Warnings and Precautions ( 5.6 ) ]. Respiratory depression is the chief risk for elderly patients treated with opioids, including Promethazine VC with Codeine Oral Solution. Respiratory depression has occurred after large initial doses of opioids were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration [see Warnings and Precautions ( 5.6 , 5.10 ) ]. Codeine is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, monitor these patients closely for respiratory depression, sedation, and hypotension. 8.6 Renal Impairment The pharmacokinetics of Promethazine VC with Codeine Oral Solution has not been characterized in patients with renal impairment. Codeine pharmacokinetics may be altered in patients with renal failure. Clearance may be decreased and the metabolites may accumulate to much higher plasma levels in patients with renal failure as compared to patients with normal renal function. Promethazine VC with Codeine Oral Solution should be used with caution in patients with severe impairment of renal function, and patients should be monitored closely for respiratory depression, sedation, and hypotension. 8.7 Hepatic Impairment No formal studies have been conducted in patients with hepatic impairment so the pharmacokinetics of Promethazine VC with Codeine Oral Solution in this patient population are unknown. Promethazine VC with Codeine Oral Solution should be used with caution in patients with impairment of hepatic function, and patients should be monitored closely for respiratory depression, sedation, and hypotension.

16 HOW SUPPLIED/STORAGE AND HANDLING Promethazine VC with Codeine Oral Solution (promethazine hydrochloride, phenylephrine hydrochloride, and codeine phosphate 6.25 mg/5 mL, 5 mg/5 mL, 10 mg/5 mL; and 7% alcohol) is a clear, reddish-orange oral solution supplied as: NDC 0121-0925-16: 1 pint (473 mL) bottle Keep bottles tightly closed. Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Protect from light. Dispense in a tight, light-resistant container with a child-resistant closure as defined in the USP. Ensure that patients have an oral dosing dispenser that measures the appropriate volume in milliliters. Counsel patients on how to utilize an oral dosing dispenser and correctly measure the oral suspension as prescribed. DEA Order Form Required

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; ULTRA-RAPID METABOLISM OF CODEINE AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine VC with Codeine Oral Solution exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Reserve Promethazine VC with Codeine Oral Solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. Assess each patient’s risk prior to prescribing Promethazine VC with Codeine Oral Solution, prescribe Promethazine VC with Codeine Oral Solution for the shortest duration that is consistent with individual patient treatment goals, monitor all patients regularly for the development of addiction or abuse, and refill only after reevaluation of the need for continued treatment [ See Warnings and Precautions ( 5.1 ) ]. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of Promethazine VC with Codeine Oral Solution. Monitor for respiratory depression, especially during initiation of Promethazine VC with Codeine Oral Solution therapy or when used in patients at higher risk [ see Warnings and Precautions ( 5.2 ) ]. Accidental Ingestion Accidental ingestion of even one dose of Promethazine VC with Codeine Oral Solution, especially by children, can result in a fatal overdose of codeine [ see Warnings and Precautions ( 5.2 ) ]. Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-Threatening Respiratory Depression in Children Life-threatening respiratory depression and death have occurred in children who received codeine. Most of the reported cases occurred following tonsillectomy and/or adenoidectomy, and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to a CYP2D6 polymorphism [ see Warnings and Precautions ( 5.3) ]. Promethazine VC with Codeine Oral Solution is contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [ see Contraindications ( 4 ) ]. Avoid the use of Promethazine VC with Codeine Oral Solution in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine. Promethazine and Respiratory Depression in Children Postmarketing cases of respiratory depression, including fatalities have been reported with use of promethazine in pediatric patients. Children may be particularly sensitive to the additive respiratory depressant effects when promethazine is combined with other respiratory depressants, including codeine [ See Warnings and Precautions ( 5.4) ]. Risk of Medication Errors Ensure accuracy when prescribing, dispensing, and administering Promethazine VC with Codeine Oral Solution. Dosing errors can result in accidental overdose and death. Always use an accurate milliliter measuring device when measuring and administering Promethazine VC with Codeine Oral Solution [ see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.7 ) ]. Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. Avoid the use of Promethazine VC with Codeine Oral Solution in patients who are taking a CYP3A4 inhibitor, CYP3A4 inducer, or 2D6 inhibitor [ see Warnings and Precautions ( 5.9) and Drug Interactions ( 7.1 , 7.2 , 7.3 ) ]. Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid the use of Promethazine VC with Codeine Oral Solution in patients taking benzodiazepines, other CNS depressants, or alcohol [See Warning and Precautions ( 5.10) and Drug Interactions ( 7.4) ]. Neonatal Opioid Withdrawal Syndrome Promethazine VC with Codeine Oral Solution is not recommended for use in pregnant women [ see Use in Specific Populations ( 8.1 ) ]. Prolonged use of Promethazine VC with Codeine Oral Solution during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If Promethazine VC with Codeine Oral Solution is used for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Warnings and Precautions ( 5.20 ) ]. WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; ULTRA-RAPID METABOLISM OF CODEINE AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME See full prescribing information for complete boxed warning. Promethazine VC with Codeine Oral Solution exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and monitor closely for these behaviors and conditions. ( 5.1 ) Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or when used in patients at higher risk. ( 5.2 ) Accidental ingestion of Promethazine VC with Codeine Oral Solution, especially by children, can result in a fatal overdose of codeine. ( 5.2 ) Life-threatening respiratory depression and death have occurred in children who received codeine; most cases followed tonsillectomy and/or adenoidectomy, and many of the children had evidence of being an ultra-rapid metabolizer of codeine due to a CYP2D6 polymorphism. ( 5.3 ) Promethazine VC with Codeine Oral Solution is contraindicated in children younger than 12 years of age and in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. ( 4 ) Avoid the use of Promethazine VC with Codeine Oral Solution in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine. Postmarketing cases of respiratory depression, including fatalities have been reported with use of promethazine in pediatric patients. Children may be particularly sensitive to the additive respiratory depressant effects when promethazine is combined with other respiratory depressants, including codeine. ( 5.4 ) Ensure accuracy when prescribing, dispensing, and administering Promethazine VC with Codeine Oral Solution. Dosing errors can result in accidental overdose and death. ( 2.1 , 5.7 ) The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. Avoid the use of Promethazine VC with Codeine Oral Solution in patients who are taking a CYP3A4 inhibitor, CYP3A4 inducer, or 2D6 inhibitor. ( 5.9 , 7.1 , 7.2 , 7.3 ) Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid the use of Promethazine VC with Codeine Oral Solution in patients taking benzodiazepines, other CNS depressants, or alcohol. ( 5.10 , 7.4 ) Promethazine VC with Codeine Oral Solution is not recommended for use in pregnant women. Prolonged use of Promethazine VC with Codeine Oral Solution during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If Promethazine VC with Codeine Oral Solution is used for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. ( 5.20 , 8.1 )